Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Conway K, Edmiston SN, Parker JS, Kuan PF, Tsai YH, Groben PA, Zedek DC, Scott GA, Parrish EA, Hao H, Pearlstein MV, Frank JS, Carson CC, Wilkerson MD, Zhao X, Slater NA, Moschos SJ, Ollila DW, Thomas NE.

J Invest Dermatol. 2019 Jun;139(6):1349-1361. doi: 10.1016/j.jid.2018.11.024. Epub 2018 Dec 6.

PMID:
30529013
2.

Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.

Thomas NE, Edmiston SN, Tsai YS, Parker JS, Googe PB, Busam KJ, Scott GA, Zedek DC, Parrish EA, Hao H, Slater NA, Pearlstein MV, Frank JS, Kuan PF, Ollila DW, Conway K.

Am J Dermatopathol. 2019 Apr;41(4):264-272. doi: 10.1097/DAD.0000000000001259.

PMID:
30211730
3.

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Thomas NE, Edmiston SN, Orlow I, Kanetsky PA, Luo L, Gibbs DC, Parrish EA, Hao H, Busam KJ, Armstrong BK, Kricker A, Cust AE, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2018 Nov;138(11):2398-2404. doi: 10.1016/j.jid.2018.04.025. Epub 2018 May 9.

4.

Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

Thomas NE, Edmiston SN, Kanetsky PA, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gruber SB, Luo L, Orlow I, Reiner AS, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Parrish EA, Hao H, Gibbs DC, Frank JS, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2017 Dec;137(12):2588-2598. doi: 10.1016/j.jid.2017.07.832. Epub 2017 Aug 24.

5.

Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

Conway K, Edmiston SN, Parrish E, Bryant C, Tse CK, Swift-Scanlan T, McCullough LE, Kuan PF.

Breast Cancer Res Treat. 2017 Jun;163(2):349-361. doi: 10.1007/s10549-017-4178-8. Epub 2017 Mar 8.

6.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

7.

IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.

Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikolaishvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS, Miller CR, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE.

Clin Cancer Res. 2015 May 1;21(9):2167-76. doi: 10.1158/1078-0432.CCR-14-1826.

8.

Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.

Conway K, Edmiston SN, Tse CK, Bryant C, Kuan PF, Hair BY, Parrish EA, May R, Swift-Scanlan T.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):921-30. doi: 10.1158/1055-9965.EPI-14-1228. Epub 2015 Mar 25.

9.

Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors.

Hair BY, Troester MA, Edmiston SN, Parrish EA, Robinson WR, Wu MC, Olshan AF, Swift-Scanlan T, Conway K.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):580-6. doi: 10.1158/1055-9965.EPI-14-1017. Epub 2015 Jan 12.

10.

DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.

Conway K, Edmiston SN, May R, Kuan PF, Chu H, Bryant C, Tse CK, Swift-Scanlan T, Geradts J, Troester MA, Millikan RC.

Breast Cancer Res. 2014 Oct 7;16(5):450. doi: 10.1186/s13058-014-0450-6.

11.

DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features.

Thomas NE, Slater NA, Edmiston SN, Zhou X, Kuan PF, Groben PA, Carson CC, Hao H, Parrish E, Moschos SJ, Berwick M, Ollila DW, Conway K.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1097-105. doi: 10.1111/pcmr.12289. Epub 2014 Jul 14.

12.

DNA-methylation profiling distinguishes malignant melanomas from benign nevi.

Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, Kuan PF, Hao H, Carson C, Berwick M, Olilla DW, Thomas NE.

Pigment Cell Melanoma Res. 2011 Apr;24(2):352-60. doi: 10.1111/j.1755-148X.2011.00828.x. Epub 2011 Feb 18.

13.

Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study.

Thomas NE, Kanetsky PA, Edmiston SN, Alexander A, Begg CB, Groben PA, Hao H, Busam K, Ollila DW, Berwick M, Conway K.

J Invest Dermatol. 2010 May;130(5):1463-5. doi: 10.1038/jid.2009.410. Epub 2009 Dec 31. No abstract available.

14.

FAK overexpression and p53 mutations are highly correlated in human breast cancer.

Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC, Cance WG.

Int J Cancer. 2009 Oct 1;125(7):1735-8. doi: 10.1002/ijc.24486.

15.

Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation.

Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Moorman P, Newman B, Millikan RC.

Breast Cancer Res. 2007;9(3):R36.

16.

Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7.

17.

IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project.

Cleveland RJ, Gammon MD, Edmiston SN, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Neugut AI, Santella RM, Conway K.

Carcinogenesis. 2006 Apr;27(4):758-65. Epub 2005 Dec 6.

PMID:
16332723
18.

The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.

Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC.

Breast Cancer Res. 2005;7(6):R871-80. Epub 2005 Sep 6.

19.

Tandem BRAF mutations in primary invasive melanomas.

Thomas NE, Alexander A, Edmiston SN, Parrish E, Millikan RC, Berwick M, Groben P, Ollila DW, Mattingly D, Conway K.

J Invest Dermatol. 2004 May;122(5):1245-50.

20.

Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.

Conway K, Edmiston SN, Cui L, Drouin SS, Pang J, He M, Tse CK, Geradts J, Dressler L, Liu ET, Millikan R, Newman B.

Cancer Res. 2002 Apr 1;62(7):1987-95.

21.

RAD1 controls the meiotic expansion of the human HRAS1 minisatellite in Saccharomyces cerevisiae.

Jauert PA, Edmiston SN, Conway K, Kirkpatrick DT.

Mol Cell Biol. 2002 Feb;22(3):953-64.

22.

Lack of association of rare alleles in the HRAS variable number of tandem repeats (VNTR) region with adult glioma.

Chen P, Wiencke JK, Conway K, Edmiston SN, Miike R, Wrensch M.

Neuro Oncol. 2000 Apr;2(2):120-4. doi: 10.1093/neuonc/2.2.120.

24.

Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia.

Walling DM, Edmiston SN, Sixbey JW, Abdel-Hamid M, Resnick L, Raab-Traub N.

Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6560-4.

Supplemental Content

Loading ...
Support Center